Page 779 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 33 Hematopoietic Tumors 757

209. Lechowski R, Jagielski D, Hoffmann-Jagielska M, et al.: Alpha- 229. Elliott JW, Cripps P, Marrington AM, et al.: Epirubicin as part of
fetoprotein in canine multicentric lymphoma, Vet Res Commun a multi-agent chemotherapy protocol for canine lymphoma, Vet
26:285–296, 2002. Comp Oncol 11:185–198, 2013.
VetBooks.ir 210. Marconato L, Crispino G, Finotello R, et al.: Clinical relevance 230. Thamm DH, Vail DM, Post GS, et al.: Alternating rabacfosadine/
doxorubicin: efficacy and tolerability in naive canine multicentric
of serial determinations of lactate dehydrogenase activity used to
lymphoma, J Vet Intern Med 31:872–878, 2017.
predict recurrence in dogs with lymphoma, J Am Vet Med Assoc
236:969–974, 2010. 231. Daters AT, Mauldin GE, Mauldin GN, et al.: Evaluation of a mul-
211. Mischke R, Waterston M, Eckersall PD: Changes in C-reactive tidrug chemotherapy protocol with mitoxantrone based mainte-
protein and haptoglobin in dogs with lymphatic neoplasia, Vet J nance (CHOP-MA) for the treatment of canine lymphoma, Vet
174:188–192, 2007. Comp Oncol 8:11–22, 2010.
212. Winter JL, Barber LG, Freeman L, et al.: Antioxidant status and 232. Garrett LD, Thamm DH, Chun R, et al.: Evaluation of a 6-month
biomarkers of oxidative stress in dogs with lymphoma, J Vet Intern chemotherapy protocol with no maintenance therapy for dogs with
Med 23:311–316, 2009. lymphoma, J Vet Intern Med 16:704–709, 2002.
213. Zizzo N, Patruno R, Zito FA, et al.: Vascular endothelial growth 233. Hosoya K, Kisseberth WC, Lord LK, et al.: Comparison of COAP
factor concentrations from platelets correlate with tumor angiogen- and UW-19 protocols for dogs with multicentric lymphoma, J Vet
esis and grading in a spontaneous canine non-Hodgkin lymphoma Intern Med 21:1355–1363, 2007.
model, Leuk Lymphoma 51:291–296, 2010. 234. Kaiser CI, Fidel JL, Roos M, et al.: Reevaluation of the University
214. Rossmeisl Jr JH, Bright P, Tamarkin L, et al.: Endostatin concentra- of Wisconsin 2-year protocol for treating canine lymphosarcoma,
tions in healthy dogs and dogs with selected neoplasms, J Vet Intern J Am Anim Hosp Assoc 43:85–92, 2007.
Med 16:565–569, 2002. 235. Keller ET, MacEwen EG, Rosenthal RC, et al.: Evaluation of
215. Flory AB, Rassnick KM, Stokol T, et al.: Stage migration in dogs prognostic factors and sequential combination chemotherapy with
with lymphoma, J Vet Intern Med 21:1041–1047, 2007. doxorubicin for canine lymphoma, J Vet Intern Med 7:289–295,
216. Raskin RE, Krehbiel JD: Prevalence of leukemic blood and bone 1993.
marrow in dogs with multicentric lymphoma, J Am Vet Med Assoc 236. MacEwen EG, Brown NO, Patnaik AK, et al.: Cyclic combina-
194:1427–1429, 1989. tion chemotherapy of canine lymphosarcoma, J Am Vet Med Assoc
217. Aresu L, Arico A, Ferraresso S, et al.: Minimal residual disease 178:1178–1181, 1981.
detection by flow cytometry and PARR in lymph node, peripheral 237. MacEwen EG, Hayes AA, Matus RE, et al.: Evaluation of some
blood and bone marrow, following treatment of dogs with diffuse prognostic factors for advanced multicentric lymphosarcoma in
large B-cell lymphoma, Vet J 200:318–324, 2014. the dog: 147 cases (1978-1981), J Am Vet Med Assoc 190:564–568,
218. Weiss DJ: Evaluation of proliferative disorders in canine bone mar- 1987.
row by use of flow cytometric scatter plots and monoclonal anti- 238. Morrison-Collister KE, Rassnick KM, Northrup NC, et al.: A
bodies, Vet Pathol 38:512–518, 2001. combination chemotherapy protocol with MOPP and CCNU
219. Ackerman N, Madewell BR: Thoracic and abdominal radiographic consolidation (Tufts VELCAP-SC) for the treatment of canine
abnormalities in the multicentric form of lymphosarcoma in dogs, lymphoma, Vet Comp Oncol 1:180–190, 2003.
J Am Vet Med Assoc 176:36–40, 1980. 239. Mutsaers AJ, Glickman NW, DeNicola DB, et al.: Evaluation of
220. Geyer NE, Reichle JK, Valdes-Martinez A, et al.: Radiographic treatment with doxorubicin and piroxicam or doxorubicin alone
appearance of confirmed pulmonary lymphoma in cats and dogs, for multicentric lymphoma in dogs, J Am Vet Med Assoc 220:1813–
Vet Radiol Ultrasound 51:386–390, 2010. 1817, 2002.
221. Jones ID, Daniels AD, Lara-Garcia A, et al.: Computed tomo- 240. Myers 3rd NC, Moore AS, Rand WM, et al.: Evaluation of a multi-
graphic findings in 12 cases of canine multi-centric lymphoma with drug chemotherapy protocol (ACOPA II) in dogs with lymphoma,
splenic and hepatic involvement, J Small Anim Pract 58:622–628, J Vet Intern Med 11:333–339, 1997.
2017. 241. Rassnick KM, Bailey DB, Malone EK, et al.: Comparison between
222. Yoon J, Feeney DA, Cronk DE, et al.: Computed tomographic L-CHOP and an L-CHOP protocol with interposed treatments of
evaluation of canine and feline mediastinal masses in 14 patients, CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in
Vet Radiol Ultrasound 45:542–546, 2004. dogs, Vet Comp Oncol 8:243–253, 2010.
223. Bassett CL, Daniel GB, Bochsler PN, et al.: Characterization of 242. Siedlecki CT, Kass PH, Jakubiak MJ, et al.: Evaluation of an acti-
uptake of 2-deoxy-2-[18F]fluoro-D-glucose by fungal-associated nomycin-D-containing combination chemotherapy protocol with
inflammation: the differential uptake ratio for blastomyces-associ- extended maintenance therapy for canine lymphoma, Can Vet J
ated lesions is as high as for lymphoma and higher than for tur- 47:52–59, 2006.
pentine abscesses in experimentally induced lesions in rats, Mol 243. Simon D, Moreno SN, Hirschberger J, et al.: Efficacy of a con-
Imaging Biol 4:193–200, 2002. tinuous, multiagent chemotherapeutic protocol versus a short-term
224. Lawrence J, Vanderhoek M, Barbee D, et al.: Use of 3’-deoxy-3’- single-agent protocol in dogs with lymphoma, J Am Vet Med Assoc
[18F]fluorothymidine PET/CT for evaluating response to cyto- 232:879–885, 2008.
toxic chemotherapy in dogs with non-Hodgkin’s lymphoma, Vet 244. Simon D, Nolte I, Eberle N, et al.: Treatment of dogs with lym-
Radiol Ultrasound 50:660–668, 2009. phoma using a 12-week, maintenance-free combination chemo-
225. LeBlanc AK, Jakoby BW, Townsend DW, et al.: 18FDG-PET therapy protocol, J Vet Intern Med 20:948–954, 2006.
imaging in canine lymphoma and cutaneous mast cell tumor, Vet 245. Sorenmo K, Overley B, Krick E, et al.: Outcome and toxicity
Radiol Ultrasound 50:215–223, 2009. associated with a dose-intensified, maintenance-free CHOP-based
226. Vail DM, Thamm DH, Reiser H, et al.: Assessment of GS-9219 chemotherapy protocol in canine lymphoma: 130 cases, Vet Comp
in a pet dog model of non-Hodgkin’s lymphoma, Clin Cancer Res Oncol 8:196–208, 2010.
15:3503–3510, 2009. 246. Valerius KD, Ogilvie GK, Mallinckrodt CH, et al.: Doxorubicin
227. Burton JH, Garrett-Mayer E, Thamm DH: Evaluation of a alone or in combination with asparaginase, followed by cyclophos-
15-week CHOP protocol for the treatment of canine multicentric phamide, vincristine, and prednisone for treatment of multicentric
lymphoma, Vet Comp Oncol 11:306–315, 2013. lymphoma in dogs: 121 cases (1987-1995), J Am Vet Med Assoc
228. Curran K, Thamm DH: Retrospective analysis for treatment of 210:512–516, 1997.
naive canine multicentric lymphoma with a 15-week, mainte- 247. Zemann BI, Moore AS, Rand WM, et al.: A combination che-
nance-free CHOP protocol, Vet Comp Oncol 14(Suppl 1):147– motherapy protocol (VELCAP-L) for dogs with lymphoma, J Vet
155, 2016. Intern Med 12:465–470, 1998.